Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BMS’ Phase III trial of melanoma drug Yervoy meets primary endpoint
A twenty-five percent reduction in the risk of recurrence or death was observed (HR = 0.75; 95% CI = 0.64-0.90; p = 0.0013). At three years, an estimated
A twenty-five percent reduction in the risk of recurrence or death was observed (HR = 0.75; 95% CI = 0.64-0.90; p = 0.0013). At three years, an estimated
OsoBio is recognized as a premier contract manufacturer of highly complex injectable drug products, including sterile liquid, suspension and lyophilized formulations. The acquisition and associated fees are expected
As previously stated, Alexion believes that it has identified the process component that resulted in the presence of the visible particles and implemented a change to the process.
Theravance, Inc., A Royalty Management Company, is focused on maximizing the potential value of the respiratory assets partnered with GlaxoSmithKline plc including RELVAR/BREO ELLIPTA and ANORO ELLIPTA and
The new business will become Horizon CombinatoRx Incorporated, a wholly owned subsidiary of Horizon. Horizon CombinatoRx, Inc. will be located in 23,000 sq. ft. of laboratory and office
Current Heel Inc. products will be available to USA distributors through August 2014, and to retailers and medical practitioners through December 2014. "We remain committed to serving the
"Sangamo’s powerful and precise ZFN-mediated genome editing technology allows us to modify a patient’s own stem cells and perform ‘autologous’ transplants, with the potential to replicate the functional
ADCs are monoclonal antibodies engineered to go unnoticed, delivering cytotoxic drugs to cells expressing the antigen target. Cancer therapy has become the most prevalent application area, with 30
ASP7374 has been produced by a cell-culture manufacturing method employing the Baculovirus Expression Vector System (BEVS), a next-generation recombinant technology platform for manufacturing biopharmaceutical products. Protein Sciences Corporation
The company’s move from its original 7,200 square foot location in Farmingdale, New York means that it will be able to manufacture new products, create more jobs, and